BR112018010964A2 - terapia de ciclo usando 3-(5-amino-2-methil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona - Google Patents
terapia de ciclo usando 3-(5-amino-2-methil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-dionaInfo
- Publication number
- BR112018010964A2 BR112018010964A2 BR112018010964A BR112018010964A BR112018010964A2 BR 112018010964 A2 BR112018010964 A2 BR 112018010964A2 BR 112018010964 A BR112018010964 A BR 112018010964A BR 112018010964 A BR112018010964 A BR 112018010964A BR 112018010964 A2 BR112018010964 A2 BR 112018010964A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinazolin
- dione
- piperidine
- oxo
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
são fornecidos aqui métodos de tratamento, prevenção e/ou gestão de câncer, incluindo linfoma, que compreendem a administração a um paciente 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona, ou um enantiômeros ou uma mistura dos seus enantiômeros, ou um seu sal, solvato, hidrato, co-cristal, clatrato ou polimorfo farmaceuticamente aceitável num regime de terapia cíclica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562262263P | 2015-12-02 | 2015-12-02 | |
PCT/US2016/064392 WO2017096024A1 (en) | 2015-12-02 | 2016-12-01 | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018010964A2 true BR112018010964A2 (pt) | 2018-12-04 |
Family
ID=57614460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018010964A BR112018010964A2 (pt) | 2015-12-02 | 2016-12-01 | terapia de ciclo usando 3-(5-amino-2-methil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona |
Country Status (13)
Country | Link |
---|---|
US (1) | US10159675B2 (pt) |
EP (1) | EP3383398A1 (pt) |
JP (1) | JP2018535992A (pt) |
KR (1) | KR20180088401A (pt) |
AU (1) | AU2016364753A1 (pt) |
BR (1) | BR112018010964A2 (pt) |
CA (1) | CA3006758A1 (pt) |
CL (1) | CL2018001434A1 (pt) |
EA (1) | EA201891289A1 (pt) |
IL (1) | IL259597A (pt) |
MX (1) | MX2018006779A (pt) |
SG (1) | SG11201804367PA (pt) |
WO (1) | WO2017096024A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
WO2018165142A1 (en) * | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
US20220008477A1 (en) | 2018-11-08 | 2022-01-13 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク. | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
GB0205395D0 (en) * | 2002-03-07 | 2002-04-24 | Univ Southampton | Materials and methods relating to the treatment of lymphoma |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
MX2007005884A (es) | 2004-11-16 | 2008-02-12 | Amgen Mountain View Inc | Andamios de proteina y usos de los mismos. |
DK2420497T3 (en) | 2006-09-26 | 2016-03-07 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
CA2829592A1 (en) * | 2011-03-11 | 2012-09-20 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
MX2013010360A (es) | 2011-03-11 | 2014-04-14 | Celgene Corp | Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos. |
WO2014004990A2 (en) * | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
AR099385A1 (es) | 2014-01-15 | 2016-07-20 | Celgene Corp | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona |
EP3166635A1 (en) * | 2014-07-11 | 2017-05-17 | Celgene Corporation | Combination therapy for cancer |
US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
EA201890585A1 (ru) | 2015-08-27 | 2018-11-30 | Селджин Корпорейшн | Составы 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |
-
2016
- 2016-12-01 US US15/367,117 patent/US10159675B2/en not_active Expired - Fee Related
- 2016-12-01 MX MX2018006779A patent/MX2018006779A/es unknown
- 2016-12-01 JP JP2018528338A patent/JP2018535992A/ja active Pending
- 2016-12-01 AU AU2016364753A patent/AU2016364753A1/en not_active Abandoned
- 2016-12-01 EA EA201891289A patent/EA201891289A1/ru unknown
- 2016-12-01 EP EP16819227.6A patent/EP3383398A1/en not_active Withdrawn
- 2016-12-01 CA CA3006758A patent/CA3006758A1/en not_active Abandoned
- 2016-12-01 SG SG11201804367PA patent/SG11201804367PA/en unknown
- 2016-12-01 KR KR1020187015154A patent/KR20180088401A/ko unknown
- 2016-12-01 BR BR112018010964A patent/BR112018010964A2/pt not_active IP Right Cessation
- 2016-12-01 WO PCT/US2016/064392 patent/WO2017096024A1/en active Application Filing
-
2018
- 2018-05-24 IL IL259597A patent/IL259597A/en unknown
- 2018-05-29 CL CL2018001434A patent/CL2018001434A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US10159675B2 (en) | 2018-12-25 |
CA3006758A1 (en) | 2017-06-08 |
KR20180088401A (ko) | 2018-08-03 |
EA201891289A1 (ru) | 2018-11-30 |
US20170157123A1 (en) | 2017-06-08 |
CL2018001434A1 (es) | 2018-08-31 |
WO2017096024A1 (en) | 2017-06-08 |
SG11201804367PA (en) | 2018-06-28 |
IL259597A (en) | 2018-07-31 |
AU2016364753A1 (en) | 2018-06-14 |
EP3383398A1 (en) | 2018-10-10 |
MX2018006779A (es) | 2018-08-01 |
JP2018535992A (ja) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124669T1 (el) | ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY | |
CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
CY1117430T1 (el) | Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονη | |
BR112015002285A2 (pt) | métodos de tratamento de câncer utilizando 3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona | |
MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
BR112017000556A2 (pt) | terapia de combinação para câncer | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
MX2015014596A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX363843B (es) | Composiciones farmaceuticas que comprenden donadores de nitroxilo. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
MX2017011277A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
MX2017008486A (es) | Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. | |
MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
BR112018010964A2 (pt) | terapia de ciclo usando 3-(5-amino-2-methil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
EA201791953A1 (ru) | Новые способы лечения рака | |
PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
TR201813294T4 (tr) | N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari. | |
BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2554 DE 17/12/2019. |